Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

NicOx Submits NDA for Osteoarthritis Drug, But Still Seeks a Commercial Partner

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

NicOx hopes a U.S. commercial partner for naproxcinod will target primary care physicians, leaving French biotech to address specialists.

You may also be interested in...



Naproxcinod Gets Joint Advisory Committee; Will It Lower NicOx's Blood Pressure?

FDA's decision to include both Arthritis Drugs and Risk Management panels in May 12 review suggests focus will on cardiovascular risks of the osteoarthritis drug.

Naproxcinod Gets Joint Advisory Committee; Will It Lower NicOx's Blood Pressure?

FDA's decision to include both Arthritis Drugs and Risk Management panels in May 12 review suggests focus will on cardiovascular risks of the osteoarthritis drug.

NicOx finds new partner Bausch & Lomb for Phase II Glaucoma Candidate

Deal shows - once again - that all is not lost when Big Pharma hands back a product

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Inside US FDA’s Return To In-Person Meetings

Pharma Gets 340B Appeals Court Victory But More Decisions Are Pending; Will Congress Step In?

US FDA’s Biggest Post-COVID Challenge May Be Helped By Small Inspections Tweak In FDORA

Accelerated Approval Price Caps: Policy Has High Profile Support – But Can It Be Done?

See All
UsernamePublicRestriction

Register

PS070033

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By